How does 1RK's PB Ratio compare to its peers?

1RK is expensive based on its Price-To-Book Ratio (154.5x) compared to the peer average (5.4x).

How does 1RK's PB Ratio compare vs other companies in the DE Biotechs Industry?

1RK is expensive based on its Price-To-Book Ratio (154.5x) compared to the European Biotechs industry average (2.5x).

What is 1RK's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 1RK's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 1RK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 1RK's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Inhibrx (DB:1RK) - Stock Price, News & Analysis

1RK Stock Overview

A clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.

About the company

1RK fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 59.66% per year

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have meaningful revenue ($2M)

Inhibrx, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€870.5m

4SC

DB:VSC

€61.5m

Heidelberg Pharma

XTRA:HPHA

€121.2m

Price History & Performance

Summary of all time highs, changes and price drops for Inhibrx
Historical stock prices
Current Share Price	US$31.00
52 Week High	US$38.00
52 Week Low	US$13.40
Beta	2.88
11 Month Change	-1.90%
3 Month Change	-7.74%
1 Year Change	42.20%
33 Year Change	96.20%
5 Year Change	n/a
Change since IPO	14.81%

Recent updates

Shareholder Returns

	1RK	DE Biotechs	DE Market
7D	-1.3%	-0.4%	-1.8%
1Y	42.2%	-14.9%	13.2%

Return vs Industry: 1RK exceeded the German Biotechs industry which returned -26.1% over the past year.

Return vs Market: 1RK exceeded the German Market which returned 5.2% over the past year.

Price Volatility

Is 1RK's price volatile compared to industry and market?
1RK volatility
1RK Average Weekly Movement	1.7%
Biotechs Industry Average Movement	6.1%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 1RK has not had significant price volatility in the past 3 months.

Volatility Over Time: 1RK's weekly volatility has decreased from 8% to 2% over the past year.

About the Company

Founded	Employees	CEO	Website
2009	169	Mark Lappe	inhibrx.com

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.

Inhibrx, Inc. Fundamentals Summary

How do Inhibrx's earnings and revenue compare to its market cap?
1RK fundamental statistics
Market cap	€1.65b
Earnings (TTM)	-€250.68m
Revenue (TTM)	€1.65m

1,002x

P/S Ratio

-6.6x

P/E Ratio

Is 1RK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1RK income statement (TTM)
Revenue	US$1.78m
Cost of Revenue	US$218.11m
Gross Profit	-US$216.32m
Other Expenses	US$54.83m
Earnings	-US$271.15m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-5.17
Gross Margin	-12,132.47%
Net Profit Margin	-15,207.80%
Debt/Equity Ratio	1,799.9%

How did 1RK perform over the long term?

See historical performance and comparison

1RK Stock Overview

Rewards

Risk Analysis

Inhibrx, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:FYB

€870.5m

DB:VSC

€61.5m

XTRA:HPHA

€121.2m

Price History & Performance

Recent News & Updates

Inhibrx Files Form 15

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Recent updates

Inhibrx Files Form 15

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Full year 2023 earnings released: US$5.12 loss per share (vs US$3.62 loss in FY 2022)

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

New major risk - Share price stability

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings released: US$1.12 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$3.62 loss per share (vs US$2.15 loss in FY 2021)

High number of new and inexperienced directors

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Third quarter 2022 earnings released: US$0.90 loss per share (vs US$0.54 loss in 3Q 2021)

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Second quarter 2022 earnings released: US$0.97 loss per share (vs US$0.55 loss in 2Q 2021)

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.51 loss in 1Q 2021)

High number of new and inexperienced directors

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Inhibrx, Inc. Announces Initial Phase 1 Dose Escalation Results for INBRX-106

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.77 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.55 loss per share (vs US$0.98 loss in 2Q 2020)

Inhibrx, Inc.(NasdaqGM:INBX) dropped from Russell 3000E Value Index

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study

First quarter 2021 earnings released: US$0.51 loss per share (vs US$1.05 loss in 1Q 2020)

Inhibrx, Inc. Announces Results from the Single Agent Dose Escalation of the Phase 1 Study of INBRX-105

Full year 2020 earnings released: US$3.01 loss per share (vs US$2.83 loss in FY 2019)

Revenue beats expectations

New 90-day low: €18.30

Inhibrx, Inc. Announces U.S. Food and Drug Administration Granted Fast Track Designation to INBRX-109

Inhibrx, Inc. Announces Results from Part 1 of the Phase 1 Dose Escalation Trial of Inbrx-106

Arecor's Partner Inhibrx Exercises Its Option to License A New Formulation Developed by Arecor

Shareholder Returns

Price Volatility

About the Company

Inhibrx, Inc. Fundamentals Summary

1,002x

-6.6x

Earnings & Revenue